Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Jan 8, 2013

Top 25 M&A Deals of 2012

Who bought who last year? Find out here.

Top 25 M&A Deals of 2012

Big bucks were spent on M&As last year. Read on to find out which deal was worth the most. [© Ben Chams - Fotolia.com]

  • #12. Ardea

    Acquired by: AstraZeneca

    Price: $1.26 billion

    Deal Completed: June 19

    Premium: 54%

  • #11. Fougera

    Acquired by: Novartis

    Price: $1.525 billion

    Deal Completed: July 23

    Premium: N/A

  • #10. Par Pharmaceuticals

    Acquired by: TPG Capital

    Price: $1.9 billion

    Deal Completed: Sept. 28

    Premium: 37%

  • #9. Dako

    Acquired by: Agilent Technologies

    Price: $2.2 billion

    Deal Completed: June 21

    Premium: N/A

  • #8. Inhibitex

    Acquired by: Bristol-Myers Squibb

    Price: $2.5 billion

    Deal Completed: Feb. 13

    Premium: 163%

  • #7. Medicis

    Acquired by: Valeant Pharmaceuticals

    Price: $2.6 billion

    Deal Completed: Dec. 11

    Premium: 39%

  • #6. Boston Biomedical

    Acquired by: Dainippon Sumitomo Pharma

    Price: $2.63 billion9

    Deal Completed: April 24

    Premium: N/A

  • #5. Human Genome Sciences

    Acquired by: GlaxoSmithKline

    Price: $3 billion

    Deal Completed: Aug. 3

    Premium: 99%

  • #4. Gen-Probe

    Acquired by: Hologic

    Price: $3.8 billion

    Deal Completed: Aug. 1

    Premium: 20%

  • #3. Amylin Pharmaceuticals

    Acquired by: Bristol-Myers Squibb

    Price: $5.3 billion10

    Deal Completed: Aug. 8

    Premium: 101%

  • #2. Actavis Group

    Acquired by: Watson Pharmaceuticals11

    Price: $5.547 billion11

    Deal Completed: Oct. 31

    Premium: N/A

  • #1. Pharmasset

    Acquired by: Gilead Sciences

    Price: $11.2 billion

    Deal Completed: Jan. 17

    Premium: 90%

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »